Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERVIT-MS)
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and tolerability of the intranodal
administration of autologous monocyte-derived dendritic cells tolerised with Vitamin-D3 and
pulsed with myelin peptides (tolDC-VitD3) in multiple sclerosis patients . To select the most
appropriate regime for the development of future therapeutic trials.
To evaluate the preliminary proof of concept by clinical and/or radiological activity and
immunological markers.
Phase:
Phase 1
Details
Lead Sponsor:
Fundació Institut Germans Trias i Pujol
Collaborator:
Clinica Universidad de Navarra, Universidad de Navarra